These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
489 related articles for article (PubMed ID: 21803958)
1. Opening a new lipid "apo-thecary": incorporating apolipoproteins as potential risk factors and treatment targets to reduce cardiovascular risk. Jacobson TA Mayo Clin Proc; 2011 Aug; 86(8):762-80. PubMed ID: 21803958 [TBL] [Abstract][Full Text] [Related]
2. Targeting low HDL-cholesterol to decrease residual cardiovascular risk in the managed care setting. Cziraky MJ; Watson KE; Talbert RL J Manag Care Pharm; 2008 Oct; 14(8 Suppl):S3-28; quiz S30-1. PubMed ID: 19891279 [TBL] [Abstract][Full Text] [Related]
4. Optimal management of combined dyslipidemia: what have we behind statins monotherapy? Tenenbaum A; Fisman EZ; Motro M; Adler Y Adv Cardiol; 2008; 45():127-153. PubMed ID: 18230960 [TBL] [Abstract][Full Text] [Related]
5. The role of niacin in raising high-density lipoprotein cholesterol to reduce cardiovascular events in patients with atherosclerotic cardiovascular disease and optimally treated low-density lipoprotein cholesterol: baseline characteristics of study participants. The Atherothrombosis Intervention in Metabolic syndrome with low HDL/high triglycerides: impact on Global Health outcomes (AIM-HIGH) trial. AIM-HIGH Investigators Am Heart J; 2011 Mar; 161(3):538-43. PubMed ID: 21392609 [TBL] [Abstract][Full Text] [Related]
6. Medical lipid-regulating therapy: current evidence, ongoing trials and future developments. Evans M; Roberts A; Davies S; Rees A Drugs; 2004; 64(11):1181-96. PubMed ID: 15161326 [TBL] [Abstract][Full Text] [Related]
7. Molecular sources of residual cardiovascular risk, clinical signals, and innovative solutions: relationship with subclinical disease, undertreatment, and poor adherence: implications of new evidence upon optimizing cardiovascular patient outcomes. Kones R Vasc Health Risk Manag; 2013; 9():617-70. PubMed ID: 24174878 [TBL] [Abstract][Full Text] [Related]
8. 'Trig-onometry': non-high-density lipoprotein cholesterol as a therapeutic target in dyslipidaemia. Jacobson TA Int J Clin Pract; 2011 Jan; 65(1):82-101. PubMed ID: 21105969 [TBL] [Abstract][Full Text] [Related]
9. Meta-analysis of comparison of effectiveness of lowering apolipoprotein B versus low-density lipoprotein cholesterol and nonhigh-density lipoprotein cholesterol for cardiovascular risk reduction in randomized trials. Robinson JG; Wang S; Jacobson TA Am J Cardiol; 2012 Nov; 110(10):1468-76. PubMed ID: 22906895 [TBL] [Abstract][Full Text] [Related]
15. Niacin as a component of combination therapy for dyslipidemia. Miller M Mayo Clin Proc; 2003 Jun; 78(6):735-42. PubMed ID: 12934785 [TBL] [Abstract][Full Text] [Related]
16. Thinking beyond low-density lipoprotein cholesterol: strategies to further reduce cardiovascular risk. Sharma RK; Singh VN; Reddy HK Vasc Health Risk Manag; 2009; 5():793-9. PubMed ID: 19812691 [TBL] [Abstract][Full Text] [Related]
17. Dose-response characteristics of cholesterol-lowering drug therapies: implications for treatment. Schectman G; Hiatt J Ann Intern Med; 1996 Dec; 125(12):990-1000. PubMed ID: 8967711 [TBL] [Abstract][Full Text] [Related]
18. Changes in plasma apolipoprotein B-containing lipoparticle levels following therapy with fluvastatin and cholestyramine. European Fluvastatin Study Group. Bard JM; Ose L; Hagen E; Duriez P; Pfister P; Fruchart JC; Dallongeville J Am J Cardiol; 1995 Jul; 76(2):65A-70A. PubMed ID: 7604802 [TBL] [Abstract][Full Text] [Related]
19. New dimension of statin action on ApoB atherogenicity. Chapman MJ; Caslake M; Packard C; McTaggart F Clin Cardiol; 2003 Jan; 26(1 Suppl 1):I7-10. PubMed ID: 12539816 [TBL] [Abstract][Full Text] [Related]
20. On-treatment non-high-density lipoprotein cholesterol, apolipoprotein B, triglycerides, and lipid ratios in relation to residual vascular risk after treatment with potent statin therapy: JUPITER (justification for the use of statins in prevention: an intervention trial evaluating rosuvastatin). Mora S; Glynn RJ; Boekholdt SM; Nordestgaard BG; Kastelein JJ; Ridker PM J Am Coll Cardiol; 2012 Apr; 59(17):1521-8. PubMed ID: 22516441 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]